How do you decide between enrolling an oligometastatic NSCLC patient on LU-002 versus treating them with SBRT off trial?

On behalf of @Dr. First Last, MD, PhD and @Dr. First Last, MD

This question is very important and goes towards the question of equipoise from the perspective of the physician and patient for enrollment on NRG-LU002, accounting for recent data from Gomez et al and Palma et al presented at ASTRO 2018. ...